Nature Communications: Shanghai Science and Technology Okura Yong team reveals a new mechanism for cancer to escape immunotherapy in tumor evolution

At present, cancer immunotherapy, including immune checkpoint blockade such as PD-1 antibody, mainly releases T cells to kill tumor cells, thereby improving the survival prospects of cancer patients

Traditional research mainly conducts deep gene sequencing on patient samples with different curative effects.

Recently, the Cang Yong team and collaborators from the School of Life Sciences and Technology of Shanghai University of Science and Technology published an online research paper titled Tumor evolution selectively inactivates the core microRNA machinery for immune evasion in Nature Communications .

They tracked the dynamic changes of tumor gene mutations under different immune stress selections through mouse models, combined with CRISPR library screening, and found that tumor cells selectively inactivate the core miRNA machinery during the evolution process, thereby escaping the killing and killing of the immune system.

Starting from the evolution of tumors, Cang Yong’s team revealed a new tumor immune escape mechanism, provided a new strategy for exploring the mechanism, and provided a new theoretical basis for the classification of cancer immunotherapy patients

MiRNA machinery regulates tumor immunity model diagram: ANKRD52 induces miRNA to bind to SOCS1 by regulating the dephosphorylation of AGO2, thereby promoting tumor cells to secrete CXCL9 and CXCL10 chemokines to recruit T cells, and affect the antigen presentation of tumor cells and the secretion of T cells IFNγ cytokine response ability, thereby regulating the recognition and killing of tumor cells by T cells

Song Tianyu, a postdoctoral fellow in Cang Yong's research group, is the first author of this article, and Long Min, a PhD student at Zhejiang University, and Zhao Haixin from WuXi AppTec's Cancer Immunology Department are the co-first authors

Original source:

Song, TY.